Skip to main content

Table 5 Statistical comparison of the results obtained from EMP, LIN, and MET in Trijardy® tablet by the Current HPLC method and a reported HPLC method

From: HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application

Parameters

EMP

LIN

MET

Reported method a

[23]

Current method

Reported method a

[23]

Current method

Reported method a

[23]

Current method

Mean

99.65

101.20

99.65

99.08

99.96

99.59

SD

0.388

0.355

0.357

1.272

0.250

0.671

Variance

0.151

0.126

0.127

1.618

0.063

0.450

t-testb

---

0.20

(2.78)

---

1.43

(2.78)

---

1.12

(2.78)

F-testb

---

1.19

(19.00)

---

12.70

(19.00)

---

7.20

(19.00)

  1. a Reversed phase HPLC-DAD employing Agilent C18 column (4.6 × 250 mm, 5 μm p.s.) and a mobile phase composed of methanol and 0.01 M sodium di-hydrogen orthophosphate buffer of pH 2.55 (adjusted with ortho-phosphoric acid) eluted in a gradient mode with detection at 218 and 224 nm.
  2. b The theoretical values of t and F at P = 0.05 are (2.78) and (19.00), respectively where n = 3.
  3. EMP, empagliflzin; LIN, linagliptin; MET, metformin.